Literature DB >> 19817077

Psycho-oncology: review and update.

Kathryn M Kash1, Rajnish Mago, Shannon Duffany, Elisabeth J S Kunkel.   

Abstract

The field of psycho-oncology is moving forward rapidly, especially for a relatively new field. Cancer patients and survivors are willing to discuss their needs and interests relating to diagnosis and treatment. There are guidelines and algorithms for determining levels of distress in cancer patients in both inpatient and outpatient settings. The pharmacologic treatment of distress, particularly depression, has vastly improved. Randomized controlled trials are becoming available for patients in order to determine the efficacy of psychotropic drugs. Numerous interventions are available to help cancer patients move forward with their lives. Some of these interventions began in the 1980s and have progressed to the use of complementary and alternative medicine techniques as coping strategies for cancer. With the rapid expansion of the Internet, cancer survivors' thirst for information also has grown. Many resources are available to help guide cancer patients through the maze of the diagnosis and treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 19817077     DOI: 10.1007/s11920-006-0031-1

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  53 in total

1.  Psychological distress among oncology outpatients. Prevalence and severity as measured with the Brief Symptom Inventory.

Authors:  M E Stefanek; L P Derogatis; A Shaw
Journal:  Psychosomatics       Date:  1987-10       Impact factor: 2.386

2.  A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.

Authors:  Dominique L Musselman; Wendy I Somerset; Ying Guo; Amita K Manatunga; Maryfrances Porter; Suzanne Penna; Barbara Lewison; Rebecca Goodkin; Kathryn Lawson; David Lawson; Dwight L Evans; Charles B Nemeroff
Journal:  J Clin Psychiatry       Date:  2006-02       Impact factor: 4.384

3.  The effect of fluoxetine on anxiety and depression symptoms in cancer patients.

Authors:  D Razavi; J F Allilaire; M Smith; A Salimpour; M Verra; B Desclaux; P Saltel; I Piollet; A Gauvain-Piquard; C Trichard; B Cordier; R Fresco; E Guillibert; D Sechter; J P Orth; M Bouhassira; P Mesters; P Blin
Journal:  Acta Psychiatr Scand       Date:  1996-09       Impact factor: 6.392

4.  Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Authors:  R Day; P A Ganz; J P Costantino; W M Cronin; D L Wickerham; B Fisher
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

5.  Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients.

Authors:  L S Duffy; D B Greenberg; J Younger; M G Ferraro
Journal:  Psychosomatics       Date:  1999 Jul-Aug       Impact factor: 2.386

6.  Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline.

Authors:  G Pezzella; R Moslinger-Gehmayr; A Contu
Journal:  Breast Cancer Res Treat       Date:  2001-11       Impact factor: 4.872

7.  Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy.

Authors:  Joseph A Roscoe; Gary R Morrow; Jane T Hickok; Karen M Mustian; Jennifer J Griggs; Sara E Matteson; Peter Bushunow; Raman Qazi; Brian Smith
Journal:  Breast Cancer Res Treat       Date:  2005-02       Impact factor: 4.872

Review 8.  Life stress, social support, and psychological vulnerability: epidemiological considerations.

Authors:  P A Thoits
Journal:  J Community Psychol       Date:  1982-10

9.  Social and physical health risk factors for first-onset major depressive disorder in a community sample.

Authors:  M L Bruce; R A Hoff
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1994-07       Impact factor: 4.328

10.  A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer.

Authors:  J C Holland; S J Romano; J H Heiligenstein; R G Tepner; M G Wilson
Journal:  Psychooncology       Date:  1998 Jul-Aug       Impact factor: 3.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.